FDA · Drug approval ·
FDA approval for Radicava ORS for ALS
The FDA has approved Radicava ORS (edaravone oral solution) for people with amyotrophic lateral sclerosis (ALS).
The US Food and Drug Administration has approved RADICAVA and RADICAVA ORS, which contain edaravone, as an oral solution.
RADICAVA ORS is indicated for the treatment of amyotrophic lateral sclerosis (ALS), a disease that affects nerve cells that control voluntary muscle movement.
This matters because it provides an FDA-approved oral option for patients being treated for ALS, which may help expand how treatment can be delivered.